Shopping Cart
Remove All
Your shopping cart is currently empty
GRI918013 (Synonyms: GRI-918013, GRI 918013)
Catalog No. T27433 Copy Product Info
Purity: 99.80%
🥰Excellent
GRI918013 is a compound that selectively and competitively inhibits the autocrine motility factor (ATX/NPP2), thereby suppressing tumor cell invasion and metastasis. GRI918013 binds competitively to the active site of ATX, preventing the entry of lipid substrates such as lysophosphatidylcholine (LPC). This reduces the ATX-catalyzed hydrolysis of LPC to form lysophosphatidic acid (LPA), thereby inhibiting cell invasion and metastasis associated with the ATX-LPA axis. GRI918013 exhibits an inhibitory effect on the ATX-catalyzed hydrolysis of the LPL substrate FS-3, with an IC50 of 31.42 nM and a Ki of 12.98 nM. GRI918013 can serve as a tool for studying invasion and metastasis in cancers such as melanoma, and is also suitable for research on ATX-LPA axis-related diseases, including fibrotic diseases, neuropathic pain, and cholestatic pruritus.
GRI918013
Copy Product Info🥰Excellent
Catalog No. T27433
Synonyms GRI-918013, GRI 918013
GRI918013 is a compound that selectively and competitively inhibits the autocrine motility factor (ATX/NPP2), thereby suppressing tumor cell invasion and metastasis. GRI918013 binds competitively to the active site of ATX, preventing the entry of lipid substrates such as lysophosphatidylcholine (LPC). This reduces the ATX-catalyzed hydrolysis of LPC to form lysophosphatidic acid (LPA), thereby inhibiting cell invasion and metastasis associated with the ATX-LPA axis. GRI918013 exhibits an inhibitory effect on the ATX-catalyzed hydrolysis of the LPL substrate FS-3, with an IC50 of 31.42 nM and a Ki of 12.98 nM. GRI918013 can serve as a tool for studying invasion and metastasis in cancers such as melanoma, and is also suitable for research on ATX-LPA axis-related diseases, including fibrotic diseases, neuropathic pain, and cholestatic pruritus.
Cas No. 313685-55-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | - | In Stock | |
| 5 mg | $98 | - | In Stock | |
| 10 mg | $157 | - | In Stock | |
| 25 mg | $278 | - | In Stock | |
| 50 mg | $448 | - | In Stock | |
| 100 mg | $722 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.80%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | GRI918013 is a compound that selectively and competitively inhibits the autocrine motility factor (ATX/NPP2), thereby suppressing tumor cell invasion and metastasis. GRI918013 binds competitively to the active site of ATX, preventing the entry of lipid substrates such as lysophosphatidylcholine (LPC). This reduces the ATX-catalyzed hydrolysis of LPC to form lysophosphatidic acid (LPA), thereby inhibiting cell invasion and metastasis associated with the ATX-LPA axis. GRI918013 exhibits an inhibitory effect on the ATX-catalyzed hydrolysis of the LPL substrate FS-3, with an IC50 of 31.42 nM and a Ki of 12.98 nM. GRI918013 can serve as a tool for studying invasion and metastasis in cancers such as melanoma, and is also suitable for research on ATX-LPA axis-related diseases, including fibrotic diseases, neuropathic pain, and cholestatic pruritus. |
| Targets&IC50 | ATX:31.42 nM |
| In vitro | Methods: Human melanoma A2058 cells were co-incubated with GRI918013, ATX, and LPC, then seeded into the upper chamber of a Transwell device. Chemotactic agents were added to the lower chamber, and the cells were incubated for 16 hours. The fluorescence intensity of cells that had invaded the lower chamber was then measured. Results: GRI918013 significantly inhibited A2058 cell invasion, with an IC₅₀ value of 118.79 ± 62.9 nM [1]. |
| In vivo | Methods: To evaluate the antitumor metastasis effects of GRI918013, an experimental lung metastasis model using B16-F10 mouse melanoma cells was established. C57BL/6 mice were injected with B16-F10 cells via the tail vein. Starting on day 1 post-tumor cell inoculation, GRI918013 (30 μg/mouse) was administered intraperitoneally once daily for 10 consecutive days. On day 21 post-inoculation, the mice were euthanized, their lungs were harvested, and the number of metastatic nodules on the lung surface was counted. Results: Treatment with GRI918013 significantly reduced the number of pulmonary metastatic nodules.[1] |
| Synonyms | GRI-918013, GRI 918013 |
| Molecular Weight | 433.28 |
| Formula | C17H15Cl2FN2O4S |
| Cas No. | 313685-55-1 |
| Smiles | O=C(NC=1C=CC=C(F)C1)C=2C=C(C(Cl)=CC2Cl)S(=O)(=O)N3CCOCC3 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy GRI918013 | purchase GRI918013 | GRI918013 cost | order GRI918013 | GRI918013 chemical structure | GRI918013 in vivo | GRI918013 in vitro | GRI918013 formula | GRI918013 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.